SynthesisHepatology international2025
Impact of myosteatosis on outcomes after liver transplantation: a systematic review and meta-analysis.
Synthesis in Hepatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Toll-like receptor 9-overexpressing red blood cell biomimetic microbubbles adsorb cell-free DNA to relieve steatotic liver ischemia-reperfusion injury.Materials today. Bio · 2026Article
- Myosteatosis as a prognostic biomarker for post-transplant survival and cardiometabolic outcomes: A retrospective study.Canadian liver journal · 2026Article
- Abdominal Organ Transplantation: Noteworthy Literature in 2025.Seminars in cardiothoracic and vascular anesthesia · 2026Review
- AI-based body composition score predicts survival after liver transplantation.Langenbeck's archives of surgery · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of myosteatosis on clinical outcomes following liver transplantation (LT) remains unclear.
methodsArticles evaluating the relationship between myosteatosis and the clinical outcomes of LT recipients were comprehensively retrieved from the Embase, PubMed, and Cochrane Library Central databases up to 1 October 2024.
resultsThirteen articles involving 3351 cases were included. Myosteatosis was related to increased mortality risk in patients undergoing LT (HR, 1.764; 95% CI, 1.469-2.120; p < 0.01). Patients with myosteatosis had significantly lower rates of 1-year (OR, 0.376; 95% CI, 0.299-0.473; p < 0.01), 3-year (OR, 0.429; 95% CI, 0.353-0.522; p < 0.01), and 5-year (OR, 0.448; 95% CI, 0.343-0.585; p < 0.01) overall survival (OS), higher rates of postoperative complications (OR, 2.482; 95% CI, 1.710-3.601; p < 0.01), 90-day mortality (OR, 4.097; 95% CI, 2.522-6.658; p < 0.01), and early allograft dysfunction (EAD) (OR, 2.197; 95% CI, 1.572-3.071; p < 0.01), and longer intensive care unit (ICU) (SMD, 0.411; 95% CI, 0.122-0.701; p < 0.01) and hospital stays (SMD, 0.682; 95% CI, 0.503-0.860; p < 0.01) than those without myosteatosis.
conclusionMyosteatosis is a potent predictor of poor prognosis and adverse perioperative outcomes in LT recipients. Early detection of myosteatosis can assist in guiding interventions and supportive care to improve the prognosis in the LT population. Furthermore, it is necessary to incorporate myosteatosis into clinical decision-making and selection criteria for LT.
Indexed as
Identifiers
40489025What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.